Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 28, 2018 - The FDA announced the approval of Teva/Celltrion’s Truxima (rituximab-abbs), biosimilar to Genentech/Biogen’s Rituxan® (rituximab).
Download PDF
Return to publications
